Profile of olaparib in the treatment of advanced ovarian cancer

Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center, Phoenix, AZ, 4Department of Trauma,...

Full description

Bibliographic Details
Main Authors:	Chase DM, Patel S, Shields K
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-04-01
Series:	International Journal of Women's Health
Subjects:	Olaparib PARP ovarian cancer
Online Access:	https://www.dovepress.com/profile-of-olaparib-in-the-treatment-of-advanced-ovarian-cancer-peer-reviewed-article-IJWH

Similar Items

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
by: Baldwin P, et al.
Published: (2018-11-01)

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
by: Patrycja Gralewska, et al.
Published: (2021-09-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
by: Hongyu Qin, et al.
Published: (2023-01-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Olaparib-Resistant <i>BRCA2</i><sup>MUT</sup> Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
by: Łukasz Biegała, et al.
Published: (2023-03-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
by: Chung Ying Chan, et al.
Published: (2022-10-01)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019-11-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study
by: Hamid Sheikh, et al.
Published: (2023-05-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
by: Jeffrey C.H. Goh, et al.
Published: (2022-08-01)

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program
by: A. A. Rumyantsev, et al.
Published: (2022-06-01)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
by: Setor Amuzu, et al.
Published: (2021-03-01)

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
by: Francisco Quiñonero, et al.
Published: (2022-11-01)

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
by: Helena de Castro e Gloria, et al.
Published: (2021-04-01)

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
by: Dean A. Fennell, et al.
Published: (2022-10-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
by: Qian Chen, et al.
Published: (2022-03-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
by: Isabella Faraoni, et al.
Published: (2019-09-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

Olaparib Conjugates with Selenopheno[3,2-<i>c</i>]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance
by: Marina Makrecka-Kuka, et al.
Published: (2022-11-01)

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
by: Ignacio Romero, et al.
Published: (2024-01-01)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
by: Depu Zhang, et al.
Published: (2022-08-01)

Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
by: Yuanyuan Yang, et al.
Published: (2023-12-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Yan Wei, et al.
Published: (2024-03-01)

UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway
by: Wenjing Hu, et al.
Published: (2021-09-01)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
by: Rosa Montero-Macias, et al.
Published: (2021-04-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)